The Week in Review: Deals and CRO News

Sinopharm Group could win the $3 billion auction for German generic-drug maker Radiopharm; Sinocom Pharma raised $15 million in a private placement; China Nuokang Bio-Pharma priced its IPO at $9, making the transaction worth $45 million; Hubei Guangji Pharma began construction of a $400 million biopharmaceutical park; Institut Mérieux will create a China center that includes R&D facilities; Milestone Scientific launched a China JV to develop drug delivery devices; Eli Lilly has made China’s pharmaceutical market a top priority; Merck of Germany will conduct an Asian Phase III trial of Stimuvax, its therapeutic cancer vaccine; Crown Bioscience will collaborate with Pfizer to develop novel drugs for cancers that afflict Asia; Shanghai ChemPartner said its scientists contributed to the breakthrough cancer research announced by Agios Pharma; and Medicilon/MPI Preclinical Research-Shanghai has been granted US GLP accreditation. More details... Stock Symbols: (HK: 01099) (NSDQ: NKBP) (SH: 000952) (OTCBB: MLSS) (NYSE: LLY) (XE: MRK) (NYSE: PFE)